The epidemiology of invasive group A streptococcal disease in Victoria, Australia

Kerry-Ann F O’Grady, Loraine Kelpie, Ross M Andrews, Nigel Curtis, Terence M Nolan, Gowri Selvaraj, Jonathan W Passmore, Frances Oppedisano, John A Carnie and Jonathan R Carapetis
Med J Aust 2007; 186 (11): 565-569.
  • Kerry-Ann F O’Grady1,2
  • Loraine Kelpie1,2
  • Ross M Andrews3
  • Nigel Curtis1,4,2
  • Terence M Nolan1,2
  • Gowri Selvaraj2
  • Jonathan W Passmore5
  • Frances Oppedisano2
  • John A Carnie6
  • Jonathan R Carapetis3

  • 1 University of Melbourne, Melbourne, VIC.
  • 2 Murdoch Children’s Research Institute, Melbourne, VIC.
  • 3 Menzies School of Health Research, Charles Darwin University, Darwin, NT.
  • 4 Royal Children’s Hospital, Melbourne, VIC.
  • 5 Road Safety Major Projects, Transport Accident Commission, Melbourne, VIC.
  • 6 Victorian Department of Human Services, Melbourne, VIC.



We would like to thank Dr Geoffrey Hogg and staff of the Microbiological Diagnostic Unit of the University of Melbourne, and all participating hospitals, doctors and laboratories for their assistance with this project. This work was funded by project grants from the National Health and Medical Research Council and the Victorian Department of Human Services. Jonathan Carapetis was supported by a career development award from the National Health and Medical Research Council.

Competing interests:

None identified.

  • 1. Stevens DL. Invasive group A streptococcus infections. Clin Infect Dis 1992; 14: 2-11.
  • 2. Stevens DL, Tanner MH, Winship J, et al. Severe group A streptococcal infections associated with a toxic shock-like syndrome and scarlet fever toxin A. N Engl J Med 1989; 321: 1-7.
  • 3. Stevens DL. Streptococcal toxic-shock syndrome: spectrum of disease, pathogenesis, and new concepts in treatment. Emerg Infect Dis 1995; 1: 69-78.
  • 4. Norton R, Smith HV, Wood N, et al. Invasive group A streptococcal disease in North Queensland (1996–2001). Indian J Med Res 2004; 119 Suppl: 148-151.
  • 5. Carapetis JR, Walker AM, Hibble M, et al. Clinical and epidemiological features of group A streptococcal bacteraemia in a region with hyperendemic superficial streptococcal infection. Epidemiol Infect 1999; 122: 59-65.
  • 6. Carapetis J, Robins-Browne R, Martin D, et al. Increasing severity of invasive group A streptococcal disease in Australia: clinical and molecular epidemiological features and identification of a new virulent M-nontypeable clone. Clin Infect Dis 1995; 21: 1220-1227.
  • 7. Norrby-Teglund A, Kaul R, Low DE, et al. Plasma from patients with severe invasive group A streptococcal infections treated with normal polyspecific IgG inhibits streptococcal superantigen-induced T cell proliferation and cytokine production. J Immunol 1996; 156: 3057-3064.
  • 8. Basma H, Norrby-Teglund A, McGeer A, et al. Opsonic antibodies to the surface M protein of group A streptococci in pooled normal immunoglobulins (IVIG): potential impact on the clinical efficacy of IVIG therapy for severe invasive group A streptococcal infections. Infect Immun 1998; 66: 2279-2283.
  • 9. Kaul R, McGeer A, Norrby-Teglund A, et al. Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome — a comparative observational study. The Canadian Streptococcal Study Group. Clin Infect Dis 1999; 28: 800-807.
  • 10. Mascini EM, Jansze M, Schouls LM, et al. Penicillin and clindamycin differentially inhibit the production of pyrogenic exotoxins A and B by group A streptococci. Int J Antimicrob Agents 2001; 18: 395-398.
  • 11. Darenberg J, Ihendyane N, Sjolin J, et al. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial. Clin Infect Dis 2003; 37: 333-340.
  • 12. Dale JB, Penfound T, Chiang EY, et al. Multivalent group A streptococcal vaccine elicits bactericidal antibodies against variant M subtypes. Clin Diagn Lab Immunol 2005; 12: 833-836.
  • 13. Bisno AL, Rubin FA, Cleary PP, Dale JB. Prospects for a group A streptococcal vaccine: rationale, feasibility, and obstacles — report of a National Institute of Allergy and Infectious Diseases workshop. Clin Infect Dis 2005; 41: 1150-1156.
  • 14. Olive C, Hsien K, Horvath A, et al. Protection against group A streptococcal infection by vaccination with self-adjuvanting lipid core M protein peptides. Vaccine 2005; 23: 2298-2303.
  • 15. McMillan DJ, Chhatwal GS. Prospects for a group A streptococcal vaccine. Curr Opin Mol Ther 2005; 7: 11-16.
  • 16. Pichichero ME. Group A streptococcal vaccines. JAMA 2004; 292: 738-739.
  • 17. McNeil SA, Halperin SA, Langley JM, et al. Safety and immunogenicity of 26-valent group a streptococcus vaccine in healthy adult volunteers. Clin Infect Dis 2005; 41: 1114-1122.
  • 18. Defining the group A streptococcal toxic shock syndrome. Rationale and consensus definition. The Working Group on Severe Streptococcal Infections. JAMA 1993; 269: 390-391.
  • 19. Clinical and Laboratory Standards Institute. Performance of standards for antimicrobial susceptibility testing; sixteenth informational supplement (CLSI document M100-S16). Wayne, Pa: CLSI, 2006.
  • 20. Al Mazrou AM. Group A streptococcal bacteraemia: experience at a university hospital in Riyadh. J Infect 1997; 34: 95-100.
  • 21. Andersen MM, Ronne T. Group A streptococcal bacteraemias in Denmark 1987–89. J Infect 1995; 31: 33-37.
  • 22. Chiobotaru P, Yagupsky P, Fraser D, Dagan R. Changing epidemiology of invasive Streptococcus pyogenes infections in southern Israel: differences between two ethnic population groups. Pediatr Infect Dis J 1997; 16: 195-199.
  • 23. Zurawski CA, Bardsley M, Beall B, et al. Invasive group A streptococcal disease in metropolitan Atlanta: a population-based assessment. Clin Infect Dis 1998; 27: 150-157.
  • 24. Bessen D, Carapetis J, Beall B, et al. Contrasting molecular epidemiology of group A streptococcus causing tropical and non-tropical infections of the skin and throat. J Infect Dis 2000; 182: 1109-1116.
  • 25. Kakis A, Gibbs L, Eguia J, et al. An outbreak of group A streptococcal infection among health care workers. Clin Infect Dis 2002; 35: 1353-1359.
  • 26. Bernaldo de Quiros JC, Moreno S, Cercenado E, et al. Group A streptococcal bacteremia: a 10 year prospective study. Medicine (Baltimore) 1997; 76: 238-248.
  • 27. Ramage L, Green K, Pyskir D, Simor AE. An outbreak of fatal nosocomial infections due to group A streptococcus on a medical ward. Infect Control Hosp Epidemiol 1996; 17: 429-431.
  • 28. Weber DJ, Rutala WA, Denny FWJ. Management of healthcare workers with pharyngitis or suspected streptococcal infections. Infect Control Hosp Epidemiol 1996; 17: 753-761.
  • 29. Centers for Disease Control and Prevention. Prevention of invasive group A streptococcal disease among household contacts of case patients and among postpartum and postsurgical patients: recommendations from the Centers for Disease Control and Prevention. Clin Infect Dis 2002; 35: 950-959.
  • 30. Abuhammour A, Hasan RA, Unuvar E. Group A beta-hemolytic streptococcal bacteremia. Indian J Pediatr 2004; 71: 915-919.
  • 31. Laupland KB, Davies D, Low DE, et al. Invasive group A streptococcal disease in children and association with varicella-zoster virus infection. Pediatrics 2000; 105: e60.
  • 32. Tyrrell GJ, Lovgren M, Kress B, Grimsrud K. Invasive group A streptococcal disease in Alberta, Canada (2000 to 2002). J Clin Microbiol 2005; 43: 1678-1683.
  • 33. Carapetis JR, Russell DM, Curtis N. The burden and cost of hospitalised varicella and zoster in Australian children. Vaccine 2004; 23: 755-761.
  • 34. Jousimies-Solmer H, Savolainen S, Makitie A, Ylikoski J. Bacteriologic findings in peritonsillar abscesses in young adults. Clin Infect Dis 1993; 16 Suppl 4: S292-S298.
  • 35. Communicable Diseases Network Australia. Guidelines for the early clinical and public health management of meningococcal disease in Australia. Canberra: Commonwealth Department of Health and Ageing, 2001. (accessed Apr 2007).
  • 36. Norrby-Teglund A, Muller MP, McGeer A, et al. Successful management of severe group A streptococcal soft tissue infections using an aggressive medical regimen including intravenous polyspecific immunoglobulin together with a conservative surgical approach. Scand J Infect Dis 2005; 37: 166-172.
  • 37. American Academy of Pediatrics Committee on Infectious Diseases. Severe invasive group A streptococcal infections: a subject review. Pediatrics 1998; 101: 136-140.
  • 38. Mulla ZD. Treatment options in the management of necrotising fasciitis caused by group A streptococcus. Expert Opin Pharmacother 2004; 5: 1695-1700.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.